

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

1-45. (Cancelled).

46. (Currently amended) A method for promoting neurite outgrowth or promoting neuronal protection against neuronal damage ~~reducing spatial or declarative memory dysfunction caused by damaged hippocampal tissue~~ in a mammal exhibiting spatial or declarative memory dysfunction, comprising the steps of: determining the existence of spatial or declarative memory dysfunction, and administering OP-1 to the mammal; wherein the spatial or declarative memory dysfunction is caused ~~damaged hippocampal tissue is damaged~~ by ibotenic acid, ammonia and formaldehyde; and wherein OP-1 promotes neurite outgrowth or promotes neuronal protection against neuronal damage.

47. (Cancelled).

48. (Currently amended) A method for promoting neurite outgrowth or promoting neuronal protection against neuronal damage ~~reducing spatial or declarative memory dysfunction caused by damaged hippocampal tissue~~ in a mammal exhibiting spatial or declarative memory dysfunction, comprising the steps of: determining the existence of spatial or declarative memory dysfunction, and administering OP-1 to the mammal; wherein the spatial or declarative memory dysfunction is caused ~~damaged hippocampal tissue is damaged~~ by malnutrition, glucose metabolism disorder, or anorexia; and wherein OP-1 promotes neurite outgrowth or promotes neuronal

protection against neuronal damage.

49-50. (Canceled).

51. (Previously presented) The method of claim 48, wherein the mammal is afflicted with malnutrition.
52. (Previously presented) The method of claim 48, wherein the mammal is afflicted with a glucose metabolism disorder.
53. (Previously presented) The method of claim 48, wherein the mammal is afflicted with anorexia.
54. (Previously presented) The method of claim 46 or 48, wherein said OP-1 comprises residues 30-292 of SEQ ID NO:2.
55. (Previously presented) The method of claim 46 or 48, wherein said OP-1 comprises residues 330-431 of SEQ ID NO:2.
56. (Previously presented) The method of claim 46 or 48, wherein said OP-1 comprises residues 48-292 of SEQ ID NO:2.
57. (Previously presented) The method of claim 46 or 48, wherein said OP-1 comprises the amino acid sequence of SEQ ID NO:2.
58. (Previously presented) The method of claim 46 or 48, wherein said OP-1 comprises a mature form of human OP-1, defined by residues 293-431 of SEQ ID NO: 2.
59. (Previously presented) The method of claim 46 or 48, wherein the OP-1 is administered by intraventricular administration.
60. (Previously presented) The method of claim 46 or 48, wherein the OP-1 is disposed in a biocompatible microsphere.